The success of the COVID-19 mRNA vaccines has demonstrated the potential of RNA vaccines and therapies. Over the next decade, RNA is poised to become a central drug platform for treating a wide range of human diseases.

Accessible services include RNA design, plasmid amplification and linearisation, RNA manufacture (1-5mg), and the necessary analytics to ensure a high-quality product. RNA manufacture is supported by appropriate quality systems that enable best-practise standards, ensuring documented and robust, scalable processes.

Current production capabilities include: